Dr. Payne’s Team Saves Employee. Read more and watch the video

Phoenix Neurological Associates, LTD was just named one of seven international centers of Excellence for Guillan Barre and CIDP. Read more

BITE NITE 2010
Our first fundraiser took place on June 5, 2010 at Scottsdale Resort and Conference Center. PNA Center for Neurological Research teamed up with the ALS Association Arizona Chapter to co-host a night dedicated to ALS (Lou Gehrig’s Disease). BITE NITE consisted of 5 top Valley Restaurants, 5th and Wine, Cien Agaves Tacos & Tequila, Oregano's Pizza Bistro and Va Bene who served up samplers of their best dishes, with great entertainment by our favorite local band Dearspeak, with silent and live auctions. The night was an absolute blast and a success. People enjoyed great food while enjoying each other’s company for a night that was dedicated to funding ALS research. Thank you for everyone who truly made this night a success. Due to the positive praise and feedback, BITE NITE will be an annual event, so if you weren’t able to attend, we look forward to seeing you there next year! Thanks again for your support, dedication and contributions, we couldn’t have made this night possible without you.

Check out photos from BITE NITE here.

Pharmacokinetic And Pharmacodynamic Study With Patients With Amyotrophic Lateral Sclerosis (ALS)

Trial Status
Open for Enrollment

What is the Purpose of this Study?
To demonstrate a pharmacodynamic effect of CK-2017357 on measures of skeletal muscle function or fatigability in patients with ALS to determine if this compound could be a potential new therapy for improving muscle weakness and muscle fatigue in patients with ALS.

Who is Eligible?
Patients 18 years or older who. Have probable or definite criteria for a diagnosis of ALS and other criteria that will be later explained in detail by the study coordinator

What is involved in this Study?
Patients will be randomized to one of six different treatment sequences. Each treatment sequence consists of three dosing periods in which patients receive single oral doses of placebo, 250 mg, and 500 mg of CK-2017357. All six treatment sequences will enroll approximately the same number of patients. A washout-out period of at least 6 days (to a maximum of 10 days) will be employed between the doses for each patient.

How long is the Study?
The study is approximately 2 months long.

For more information contact: Lynne E. Flynn, CCRC, study coordinator, at 602-258-2863 or lynneflynn@pnal.net